Moreover, treatment of CRC patients with the anti-VEGF-A monoclonal antibody bevacizumab reversed Treg accumulation in patients’ blood (58) whilst VEGFR2+CD4+Foxp3+ cells are reportedly associated with poor prognosis in CRC (59) supporting the theory that angiogenic factors may be targeted for the purpose of modulating both angiogenesis and the anti-tumor immune response. The gene discussed is CD4; the disease is neoplasm.